Literature DB >> 32785780

Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis.

Cem Yalaza1, Necmiye Canacankatan2, İclal Gürses3, Hakan Aytan4, Bahar Taşdelen5.   

Abstract

PURPOSE: Adenomyosis is a benign uterine disease resulting from the myometrial invasion of the endometrial gland and stroma. In the current study, angiogenesis, apoptosis and energy metabolism were investigated in adenomyosis.
METHODS: A retrospective study was performed using paraffin archival tissues. Three groups were included in the study: Group I and Group II; ectopic and eutopic endometrial tissues of patients with adenomyosis, respectively, and Control Group; endometrial tissue of individuals without adenomyosis. Vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), intercellular adhesion molecule 1 (ICAM-1) and hypoxia-inducible factor 1 alpha (HIF-1A) levels were evaluated as angiogenic markers. Bcl-2, caspase-9 and caspase-3 levels were investigated as apoptotic indicators, and isocitrate dehydrogenase 1 (IDH1), succinate dehydrogenase complex subunit C (SDHC) and fumarate hydratase (FH) levels were also examined as energy metabolism markers. Gene expression levels of all parameters were determined by RT-PCR. RESULT: VEGF expression levels were found to be increased in Group I according to the control group and Group II. Bcl-2 expression levels were found to be increased in the Group I compared to the Group II. It was determined that expression levels of IDH1 were decreased in the Group I and Group II compared to the Control Group. There was no significant difference in the other examined parameters. Although we did not find a significant difference in HIF-1A levels between the groups, we found a positive correlation between VEGF and HIF-1A in the Group I.
CONCLUSION: These results point out that VEGF, HIF-1A, Bcl-2 and IDH1 may be associated with the etiology of adenomyosis.

Entities:  

Keywords:  Adenomyosis; Bcl-2; HIF-1A; IDH1; VEGF

Mesh:

Substances:

Year:  2020        PMID: 32785780     DOI: 10.1007/s00404-020-05742-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  2 in total

1.  [Study on the expression of vascular endothelial growth factor in patients with adenomyosis of the uterus].

Authors:  Yanhua Han; Yingfang Zhou; Shurong Zheng
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2002-09

Review 2.  Adenomyosis and its impact on women fertility.

Authors:  Elisabetta Garavaglia; Serafini Audrey; Inversetti Annalisa; Ferrari Stefano; Tandoi Iacopo; Corti Laura; Candiani Massimo
Journal:  Iran J Reprod Med       Date:  2015-06
  2 in total
  5 in total

1.  Effect of Neiyi Prescription of QIU on autophagy and angiogenic ability of endometriosis via the PPARγ/NF-κB signaling pathway.

Authors:  Hua-Di Yang; Qun-Fei Zhu; Hui Li; Xue-Lu Jiang; Xu-Qun Xu; Yong Guo
Journal:  Arch Gynecol Obstet       Date:  2022-04-03       Impact factor: 2.493

2.  A clinical scoring system for the diagnosis of adenomyosis.

Authors:  Muhammet Yıldırır; Hakan Aytan; Hüseyin Durukan; İclal Gürses
Journal:  Turk J Obstet Gynecol       Date:  2022-06-27

3.  Upregulated Talin1 synergistically boosts β-estradiol-induced proliferation and pro-angiogenesis of eutopic and ectopic endometrial stromal cells in adenomyosis.

Authors:  Yi-Yi Wang; Hua Duan; Sha Wang; Yong-Jun Quan; Jun-Hua Huang; Zheng-Chen Guo
Journal:  Reprod Biol Endocrinol       Date:  2021-05-14       Impact factor: 5.211

4.  How does the extent of fibrosis in adenomyosis lesions contribute to heavy menstrual bleeding?

Authors:  Qingqing Huang; Xishi Liu; Hilary Critchley; Zhongpeng Fu; Sun-Wei Guo
Journal:  Reprod Med Biol       Date:  2022-02-07

5.  Analysis of the Mechanism of GuizhiFuling Wan in Treating Adenomyosis Based on Network Pharmacology Combined with Molecular Docking and Experimental Verification.

Authors:  Yaxin Shi; Chengyuan Zhang; Xin Wang; Zilu Wang; Yiran Zhang; Zhiyong Liu; Xin Wang; Wei Shi
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-26       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.